

CITATION REPORT

List of articles citing

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

DOI: 10.1161/circulationaha.119.044059
Circulation, 2020, 141, 1384-1392.

Source: <https://exaly.com/paper-pdf/77026140/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
59	Direct oral anticoagulants in chronic kidney disease: an update. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 489-496	3.5	0
58	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1847-1948	3.8	82
57	Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1309-1327	3.8	2
56	Opportunities to optimise direct-acting oral anticoagulants. <i>The Prescriber</i> , 2020 , 31, 34-35	0.4	
55	Effects of Anti-vitamin k oral anticoagulants on bone and cardiovascular health. <i>European Journal of Internal Medicine</i> , 2020 , 79, 1-11	3.9	2
54	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET). <i>Journal of Nephrology</i> , 2021 , 34, 31-38	4.8	3
53	Use of DOAC in Patients with Kidney Disease. 2021 , 121-130		
52	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 273-281	3.9	5
51	Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 1474-1483	12.7	17
50	Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	0
49	Renal Disease and Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021 , 13, 95-112	1.4	2
48	Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?. <i>European Journal of Haematology</i> , 2021 , 106, 689-696	3.8	2
47	Comparison of the Safety and Efficacy of Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation or Venous Thromboembolism in Patients with Renal Impairment: Systematic Review, Meta-Analysis and Network Meta-Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 643-657	4	2
46	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	
45	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
44	Apixaban versus Warfarin in Patients with Chronic Kidney Disease; A Systematic Review and Meta-analysis. <i>Korean Journal of Clinical Pharmacy</i> , 2021 , 31, 87-95	0.2	
43	Antiarrhythmic Drugs for Atrial Fibrillation in the Outpatient Setting: Common Clinical Scenarios and Pearls for the Primary Care Clinician. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2230-2242	6.4	

42	Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021 , 39, 435-446	2.5	1
41	Is Warfarin Being Relegated to the Pharmaceutical Dustbin?. <i>American Journal of Kidney Diseases</i> , 2021 , 78, 174-176	7.4	
40	CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. <i>American Journal of Kidney Diseases</i> , 2021 , 78, 180-189	7.4	3
39	Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021 , 39, 415-425	2.5	
38	Can direct oral anticoagulants be used in kidney transplant recipients?. <i>Clinical Transplantation</i> , 2021 , e14474	3.8	0
37	Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. <i>Frontiers in Medicine</i> , 2021 , 8, 654620	4.9	
36	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 76, 671-677	3.1	3
35	Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4676	1.3	
34	Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 752468	5.4	0
33	Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. <i>Contemporary Cardiology</i> , 2021 , 611-651	0.1	
32	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and Siset. <i>Blood Transfusion</i> , 2020 , 18, 478-485 ^{3,6}		
31	Antithrombotic Therapy in the Prevention of Stroke.. <i>Biomedicines</i> , 2021 , 9,	4.8	0
30	Comparative Safety and Effectiveness of Apixaban vs. Warfarin in Oral Anticoagulant-Naïve Japanese Patients With Non-Valvular Atrial Fibrillation - A Retrospective Chart Review Study.. <i>Circulation Journal</i> , 2021 , 86,	2.9	0
29	Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	1
28	Fibrilaci3 auricular no valvular en pacientes en hemodi3lisis cr3nica. ¿Debemos anticoagular?. <i>Nefrologia</i> , 2022 ,	1.5	0
27	Use of Non-Vitamin K Dependent Oral Anticoagulant in Ischemic Stroke. <i>Journal of the Korean Neurological Association</i> , 2022 , 40, 1-14	0.1	
26	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases.. <i>European Heart Journal Supplements</i> , 2022 , 24, A11-A18	1.5	
25	Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation: Rationale and Design of the RED-AF study.. <i>American Heart Journal</i> , 2022 , 248, 42-42	4.9	0

24	Impact of different renal function equations on direct oral anticoagulant concentrations.. <i>Scientific Reports</i> , 2021 , 11, 23833	4.9	○
23	Chronic kidney disease and anticoagulation - Quick overview and practical guide. <i>Indian Journal of Vascular and Endovascular Surgery</i> , 2022 , 9, 40	0.1	
22	Association Between Apixaban Concentration and Clinical Outcomes in Asians With Atrial Fibrillation.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022 , 101161CIRCEP121010693	6.4	○
21	?????????????. <i>Nihon Toseki Igakkai Zasshi</i> , 2022 , 55, 279-283	0.3	
20	Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3207	5.1	
19	Anticoagulants in Use. 2022 , 327-345		
18	Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	○
17	Renal function and mortality in patients with atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , Publish Ahead of Print,	1.9	
16	Stroke Prevention in Atrial Fibrillation. 2022 ,		
15	CURE: A Pre-training Framework on Large-scale Patient Data for Treatment Effect Estimation.		○
14	Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients A cohort study. 2022 , 20,		○
13	Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review. 2022 ,		○
12	Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice. 2022 ,		○
11	Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). 2022 , 220, 91-96		○
10	Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.		3
9	Treatment and Nursing Application of a New Heterocycle Compound on Children Bronchial Pneumonia. 2022 , 14, 1131-1136		○
8	Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry. 64,		○
7	Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D.		○

- 6 Anticoagulation for Atrial Fibrillation. Publish Ahead of Print,
- 5 The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis. **2023**, 79, 461-471
- 4 Secondary Ischemic Stroke Prevention.
- 3 Nonvalvular atrial fibrillation in patients undergoing chronic hemodialysis. Should dialysis patients with atrial fibrillation receive oral anticoagulation?. **2022**, 42, 633-644
- 2 Comparison of value of 640-slice CT kidney scan and kidney ultrasound in the diagnosis of chronic kidney disease. 1-13
- 1 Renal Function and Clinical Outcomes Among Elderly Patients With Nonvalvular Atrial Fibrillation From ANAFIE. **2023**,